sonrotoclax + azacitidine

**Sonrotoclax + azacitidine** is an investigational combination therapy for acute myeloid leukemia (AML), particularly in newly diagnosed (treatment naive, TN) or relapsed/refractory (R/R) adult AML. **Sonrotoclax** (BGB-11417) is an oral, selective BCL2 inhibitor developed to induce apoptosis in cancer cells dependent on BCL2 for survival, similar in class to venetoclax. **Azacitidine** is a hypomethylating agent that exerts antineoplastic effects via inhibition of DNA methyltransferase, promoting cell differentiation or apoptosis. The combination is being evaluated in phase II clinical studies for its antileukemic effects and safety profile in AML, where it has shown encouraging response rates and tolerability, especially in patients unfit for intensive chemotherapy or in the relapsed/refractory setting[1][3][5]. The developer of sonrotoclax is BeiGene, often in collaboration with BeOne Medicines[1][3]. Azacitidine is a widely available generic drug, originally developed by Pharmion (now Celgene/Bristol Myers Squibb).